We are live on ! Find out more
PVLA

Palvella Therapeutics

68 hedge funds and large institutions have $68.3M invested in Palvella Therapeutics in 2022 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 14 increasing their positions, 26 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

825% more call options, than puts

Call options by funds: $222K | Put options by funds: $24K

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

0.01% less ownership

Funds ownership: 0.64%0.63% (-0.01%)

4% less funds holding

Funds holding: 7168 (-3)

20% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 15

41% less capital invested

Capital invested by funds: $115M → $68.3M (-$46.6M)

46% less repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 26

Holders
68
Holders Change
-3
Holders Change %
-4.23%
% of All Funds
1.15%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
12
Increased
14
Reduced
26
Closed
15
Calls
$222K
Puts
$24K
Net Calls
+$198K
Net Calls Change
-$325K

PVLA Hedge Fund Activity: Q2 2022 in Review

68 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q2 2022, worth a combined $68.3M — down 41% from $115M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of PVLA and 12 opened new positions — a net loss of 3 holders — while 26 trimmed existing stakes and 14 added.

The largest buyer was Lynx1 Capital Management, adding an estimated $4.76M. The largest seller was Woodline Partners, exiting entirely with an estimated $4.81M sold.

  • 68 institutional investors held Palvella Therapeutics (PVLA) as of Q2 2022, down from 71 in Q1 2022.
  • Funds reported $68.3M of Palvella Therapeutics stock for Q2 2022, down 41% quarter-over-quarter.
  • 12 funds opened new Palvella Therapeutics positions in Q2 2022 and 15 closed out, a net change of -3 holders.
  • The largest Palvella Therapeutics buyer in Q2 2022 was Lynx1 Capital Management, an estimated $4.76M added.
  • The largest Palvella Therapeutics seller in Q2 2022 was Woodline Partners, an estimated $4.81M sold.

Based on aggregated 13F filings for Q2 2022.